MediPharm Labs Completes First Shipment to France
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the completion of the Company's first shipment to France.
This milestone follows a production agreement with an international medicinal cannabis organization. This strategic collaboration strengthens MediPharm's position as a trusted supplier of pharmaceutical-grade cannabis products and demonstrates the Company's ability to meet stringent European regulatory standards. The French medicinal cannabis market is projected to experience significant growth over the coming years. Conservative estimates place the market at US$187.6 million by 2025, rising to US$213.3 million by 2030 under current regulatory conditions.(1)
"MediPharm's completion of our first production order and subsequent shipment to France marks our entry into one of Europe's most promising emerging medical cannabis markets," said David Pidduck, CEO of MediPharm Labs. "This achievement underscores our ability to establish new pathways to market and deliver pharmaceutical-grade products that meet stringent European standards."
MediPharm Labs continues to expand its global footprint through strategic distribution and pharmaceutical partnerships, leveraging industry-leading licenses from multiple regulatory authorities to access new markets and deliver innovative cannabinoid-based solutions worldwide. As of Q3 2025, international medical cannabis represented 56% of MediPharm's total revenue. The 83% year-over-year growth in revenue for international medical cannabis was achieved through product portfolio expansion across multiple geographies.
MediPharm Labs has established distribution and supply partnerships across the globe, and now ships products to 10 countries, underscoring our commitment to advancing global health through trusted, compliant, and high-quality cannabinoid offerings.
(1) Statista. (2025). Medical cannabis market forecast – France. .
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Website:
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding the Company's ongoing ability to establish new pathways to market and deliver pharmaceutical-grade products that meet stringent European regulatory standards, the projected growth of the French medicinal cannabis market, and MediPharm's continued expansion of its global footprint through distribution and pharmaceutical partnerships. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
SOURCE MediPharm Labs Corp.
For further information, please contact: MediPharm Labs Investor Relations,
1 416.913.7425,
